Literature DB >> 8255474

Nerve growth factor reverses neuronal atrophy in a Down syndrome model of age-related neurodegeneration.

D M Holtzman1, Y Li, K Chen, F H Gage, C J Epstein, W C Mobley.   

Abstract

Atrophy and dysfunction of certain neurons, including cholinergic neurons in the basal forebrain, are key features of the neuropathology of Alzheimer's disease (AD). Since all individuals with Down syndrome (DS) develop AD neuropathology by the 4th decade, we reasoned that a genetic model of DS, the trisomy 16 (Ts 16) mouse, may provide an animal model to study the neurodegeneration in AD. Ts 16 mice fail to survive birth; to evaluate neurons for long periods in vivo required transplantation of fetal tissue. We previously demonstrated that Ts 16 basal forebrain cholinergic neurons (BFCNs) undergo age-related atrophy similar to DS and AD, and now show that a specific neurotrophic factor, nerve growth factor (NGF), acts to reverse Ts 16-induced atrophy of BFCNs and stimulates hypertrophy of these cells. As NGF levels were not decreased in the host, abnormalities intrinsic to Ts 16 BFCNs presumably caused the atrophy. Our results suggest that NGF may be useful in reversing cholinergic neurodegeneration in DS and AD.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8255474     DOI: 10.1212/wnl.43.12.2668

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  16 in total

1.  2001 William Allan Award Address. From Down syndrome to the "human" in "human genetics".

Authors:  Charles J Epstein
Journal:  Am J Hum Genet       Date:  2001-12-26       Impact factor: 11.025

Review 2.  On the molecular basis linking Nerve Growth Factor (NGF) to Alzheimer's disease.

Authors:  Simona Capsoni; Antonino Cattaneo
Journal:  Cell Mol Neurobiol       Date:  2006-08-31       Impact factor: 5.046

3.  A hypothalamic neuronal cell line persistently infected with scrapie prions exhibits apoptosis.

Authors:  H M Schätzl; L Laszlo; D M Holtzman; J Tatzelt; S J DeArmond; R I Weiner; W C Mobley; S B Prusiner
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

4.  Down syndrome fibroblast model of Alzheimer-related endosome pathology: accelerated endocytosis promotes late endocytic defects.

Authors:  Anne M Cataldo; Paul M Mathews; Anne Boyer Boiteau; Linda C Hassinger; Corrinne M Peterhoff; Ying Jiang; Kerry Mullaney; Rachael L Neve; Jean Gruenberg; Ralph A Nixon
Journal:  Am J Pathol       Date:  2008-06-05       Impact factor: 4.307

Review 5.  Prospects for improving brain function in individuals with Down syndrome.

Authors:  Alberto C S Costa; Jonah J Scott-McKean
Journal:  CNS Drugs       Date:  2013-09       Impact factor: 5.749

Review 6.  Viral vectors for neurotrophic factor delivery: a gene therapy approach for neurodegenerative diseases of the CNS.

Authors:  Seung T Lim; Mikko Airavaara; Brandon K Harvey
Journal:  Pharmacol Res       Date:  2009-10-17       Impact factor: 7.658

7.  Ts1Cje, a partial trisomy 16 mouse model for Down syndrome, exhibits learning and behavioral abnormalities.

Authors:  H Sago; E J Carlson; D J Smith; J Kilbridge; E M Rubin; W C Mobley; C J Epstein; T T Huang
Journal:  Proc Natl Acad Sci U S A       Date:  1998-05-26       Impact factor: 11.205

Review 8.  Neurotrophic factors and neurologic disease.

Authors:  D M Holtzman; W C Mobley
Journal:  West J Med       Date:  1994-09

Review 9.  Alzheimer disease.

Authors:  Rudy J Castellani; Raj K Rolston; Mark A Smith
Journal:  Dis Mon       Date:  2010-09       Impact factor: 3.800

10.  Cholinergic degeneration and memory loss delayed by vitamin E in a Down syndrome mouse model.

Authors:  Jason Lockrow; Annamalai Prakasam; Peng Huang; Heather Bimonte-Nelson; Kumar Sambamurti; Ann-Charlotte Granholm
Journal:  Exp Neurol       Date:  2008-12-10       Impact factor: 5.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.